PHARMACEUTICAL COMPOSITIONS COMPRISING A COMBINATION OF RAPAMYCIN OR ITS DERIVATIVE AND PIMECROLIMUS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE (IBD)

(19)

(11)

EP 1 608 368 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	10.06.2009 Bulletin 2009/24

(45)	Mention of the grant of the patent:
	01.10.2008 Bulletin 2008/40

(21)	Application number: 04720871.5

(22)	Date of filing: 16.03.2004

(51)

International Patent Classification (IPC):

A61K 31/436^(2006.01)
A61P 37/00^(2006.01)

A61K 31/445^(2006.01)

(86)	International application number:
	PCT/EP2004/002714

(87)	International publication number:
	WO 2004/082681 (30.09.2004 Gazette 2004/40)

(54)

PHARMACEUTICAL COMPOSITIONS COMPRISING A COMBINATION OF RAPAMYCIN OR ITS DERIVATIVE AND PIMECROLIMUS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE (IBD)

PHARMAZEUTISCHE ZUSAMMENSETZUNGEN MIT EINER KOMBINATION AUS RAPAMYCIN ODER SEINEN DERIVATEN UND PIMECROLIMUS ZUR BEHANDLUNG VON ENTZÜNDLICHER DARMERKRANKUNG (IBD)

COMPOSITIONS PHARMACEUTIQUES COMPRENANT UNE COMBINAISON DE RAPAMYCINE OU DE SON DERIVE ET DE PIMECROLIMUS POUR LE TRAITEMENT DE L' AFFECTION INTESTINALE INFLAMMATOIRE (IBD)

(84)	Designated Contracting States:
	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR
	Designated Extension States:
	LT LV

(30)

Priority:

17.03.2003 GB 0306070
25.03.2003 GB 0306868
15.08.2003 GB 0319226

(43)	Date of publication of application:
	28.12.2005 Bulletin 2005/52

(73)	Proprietors:
	NOVARTIS AG 4056 Basel (CH) Designated Contracting States: BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR Novartis Pharma GmbH 1230 Wien (AT) Designated Contracting States: AT

(72)	Inventor:
	MOORE, Henrietta A-2384 Breitenfurt (AT)

(56)

References cited: :

EP-A- 1 208 847
WO-A-02/089796
WO-A-03/094990

WO-A-99/24036
WO-A-03/057218
US-A- 6 004 973

MARSLAND ALEXANDER M ET AL: "The macrolide immunosuppressants in dermatology: mechanisms of action." [Online] November 2002 (2002-11), EUROPEAN JOURNAL OF DERMATOLOGY : EJD. 2002 NOV-DEC, VOL. 12, NR. 6, PAGE(S) 618 - 622 , XP002284186 ISSN: 1167-1122 John Libbey Eurotext Retrieved from the Internet: URL:http://www.john-libbey-eurotext.fr/en/ revues/medecine/ejd/e-docs/00/01/87/58/art icle.md?type=text.html> [retrieved on 2004-06-07] page 2, paragraph 5
BORNHÖVD E ET AL: "Macrolactam immunomodulators for topical treatment of inflammatory skin diseases." November 2001 (2001-11), JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY. NOV 2001, VOL. 45, NR. 5, PAGE(S) 736 - 743 , XP002284187 ISSN: 0190-9622 the whole document

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).